Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 138
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Active
0 to 30
Other
EUDRACT 2005-002618-40
BfArM-4030755, EC-105/05, DKS 2006.01, NCT00749723
Last Modified:
1/23/2007
 
First Published:
11/24/2002
2.
Phase III Randomized Study of Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Patients With Recurrent Malignant Glioma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Other
MRC-BR12
EU-20114, ISRCTN83176944, NCT00052455
Last Modified:
1/14/2009
 
First Published:
10/25/2004
3.
Phase III Randomized Study of Whole Brain Radiotherapy and Stereotactic Radiosurgery With Versus Without Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and Brain Metastases
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
NCI
RTOG-0320
NCT00096265
Last Modified:
1/6/2009
 
First Published:
9/9/2005
4.
Phase III Randomized Study of Radiotherapy Versus Temozolomide in Patients With Low-Grade Gliomas
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Other
EORTC-22033
EORTC-26033, EudraCT-2004-002714-11, CAN-NCIC-CE5, NCT00182819, TROG 06.01, CE5
5.
Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Other
TASMC-05-FB-05235-CTIL
NCT00268684
Last Modified:
1/14/2009
 
First Published:
3/13/2006
6.
Phase III Randomized Study of Adjuvant Radiation Therapy and Conventional Temozolomide Versus Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
NCI
RTOG-0525
EORTC-26052, EORTC-22053, NCT00304031
Last Modified:
6/11/2008
 
First Published:
10/21/2006
7.
Phase III Pilot Study of Induction Chemotherapy Followed by Consolidation Myeloablative Chemotherapy Comprising Thiotepa and Carboplatin With or Without Etoposide and Autologous Hematopoietic Stem Cell Rescue in Pediatric Patients With Previously Untreated Malignant Brain Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
Under 10 at diagnosis
Other
CHLA-HEAD-START-III
CHLA-HSIII, CHLA-2004-020, CHLA-04.020, NCT00392886, UMN-MT2004-06
8.
A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
LX01-315
NCT00395070
Last Modified:
10/8/2008
 
First Published:
5/23/2007
9.
Phase III Randomized Study of Short-Course Radiotherapy With or Without Temozolomide in Older Patients With Newly Diagnosed Glioblastoma Multiforme
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Biomarker/Laboratory analysis, Treatment
Active
65 and over
Other, Pharmaceutical / Industry
CAN-NCIC-CE6
EORTC-26062, EORTC-22061, CE6, SPRI-CAN-NCIC-CE.6, NCT00482677
Last Modified:
1/8/2009
 
First Published:
1/14/2008
10.
Phase III Randomized Study of Radiotherapy With or Without Concurrent and/or Adjuvant Temozolomide in Patients With Non-1p/19q Deleted Anaplastic Glioma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Biomarker/Laboratory analysis, Treatment
Active
18 and over
Other, Pharmaceutical / Industry
EORTC-26053
RTOG-0834, EORTC-22054, EUDRACT-2006-001533-17, SPRI-EORTC-26053, NCT00626990
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute